ArticleCancer medicine2017
Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study.
Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Bleeding and thrombotic events in atrial fibrillation patients with cancer: a systematic review and meta-analysis.Internal and emergency medicine · 2023Pooled it
- Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: a meta-analysis of randomized clinical trials and observational studies.European journal of clinical pharmacology · 2021Pooled it
- Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies.Frontiers in cardiovascular medicine · 2021Pooled it
- Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2019Pooled it
- Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database.Cardiovascular drugs and therapy · 2025Article
- Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer.Research and practice in thrombosis and haemostasis · 2025Article
- Major bleeding and thromboembolic complications associated with antithrombotic treatment in patients with atrial fibrillation/flutter and incident cancer.Research and practice in thrombosis and haemostasis · 2025Article
- Risk of Atrial Fibrillation in Patients with Different Cancer Types in Taiwan.Life (Basel, Switzerland) · 2024Article
- Long-term prognostic significance of history of cancer and atrial fibrillation in coronary artery disease.International journal of cardiology. Heart & vasculature · 2023Article
- Review
- Common Cancer Types and Risk of Stroke and Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Study in England.Journal of the American Heart Association · 2023Article
- Atrial fibrillation in cancer survivors - a systematic review and meta-analysis.Cardio-oncology (London, England) · 2023Article
- A retrospective evaluation of direct oral anticoagulant (DOAC) management strategies in patients with cancer on active chemotherapy.Journal of thrombosis and thrombolysis · 2023Article
- Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice.Research and practice in thrombosis and haemostasis · 2023Article
- Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors.Life (Basel, Switzerland) · 2023Review
- Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation.Frontiers in cardiovascular medicine · 2023Review
- Wearable device use and technology preferences in cancer survivors with or at risk for atrial fibrillation.Cardiovascular digital health journal · 2022Article
- Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes.Journal of clinical medicine · 2022Review
- Outcomes by Class of Anticoagulant Use for Nonvalvular Atrial Fibrillation in Patients With Active Cancer.JACC. CardioOncology · 2022Article
- Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coexisting cancer in patients with atrial fibrillation (AF) has been associated with thromboembolism and bleeding. We used Danish population-based medical databases to conduct a population-based cohort study that included all AF patients who redeemed a prescription for vitamin K antagonists (VKA) or non-VKA oral anticoagulant (NOAC) between July 2004 and December 2013. We characterized these patients according to the presence (N = 11,855) or absence (N = 56,264) of a cancer diagnosis before redemption of their oral anticoagulant prescription, and then examined their 1-year risk of thromboembolic or bleeding complications or death. We next used Cox regression to compare the hazard ratios for complications among VKA- or NOAC-treated AF patients with versus without a cancer diagnosis, after adjusting for sex, age, and CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.